glp 1 gip triple agonist Schematic illustration of monoagonists, dual agonists and Polyagonists Enable Increasingly Effective Treatment

The precise mechanisms of these effects are unknown

Extrapolation of these doses to humans, using standard allometric conversion factors (factor of 6.2 for rats), yields theoretical doses on the order of 1.6 g/kg in humans

To our knowledge, we are the first to report that nuclear GSTP functions as a negative regulator to control HMGB1 release from macrophages and decreases the mortality of sepsis

Maintenance doses are then tailored to keep those levels topped up, and their duration of effect is directly tied to the prescribed frequency (e.g., a shot every 12 weeks for many)

A deficiency left untreated long term, can result in nerve cell damage